Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP9 | P14780 | 5/20 | 0.43 |
| ▸ | MMP8 | P22894 | 5/20 | 0.43 |
| ▸ | MMP2 | P08253 | 4/20 | 0.43 |
| ▸ | ACE | P12821 | 3/20 | 0.43 |
| ▸ | MME | P08473 | 3/20 | 0.43 |
| ▸ | CPA1 | P15085 | 2/20 | 0.43 |
| ▸ | ACE2 | Q9BYF1 | 2/20 | 0.43 |
| ▸ | IDE | P14735 | 2/20 | 0.42 |
| ▸ | FCER2 | P06734 | 3/20 | 0.41 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18637421 | 0.94 | IDE (0.45) | MMP9MMP8MMP2ACEMME | |
| SCHEMBL18637664 | 0.93 | MMP9 (0.46) | MMP9MMP8MMP2ACEMME | |
| SCHEMBL18637418 | 0.92 | IDE (0.44) | MMP9MMP8MMP2ACEMME | |
| SCHEMBL19825874 | 0.88 | MME (0.53) | MME | |
| SCHEMBL23658095 | 0.88 | MME (0.53) | MME | |
| SCHEMBL18637663 | 0.87 | MMP9 (0.46) | MMP9MMP8MMP2ACEMME | |
| SCHEMBL23658069 | 0.85 | ACE (0.46) | MMP9MMP8MMP2ACEMME | |
| SCHEMBL19826074 | 0.83 | MME (0.39) | MME | |
| SCHEMBL23658057 | 0.82 | MME (0.54) | MME | |
| SCHEMBL19825792 | 0.82 | MME (0.54) | MME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210221848-A1 | POLYMYXIN DERIVATIVES AND THEIR USE IN COMBINATION THERAPY TOGETHER WITH DIFFERENT ANTIBIOTICS | SPERO THERAPEUTICS, INC. | 2021-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210221848-A1 | POLYMYXIN DERIVATIVES AND THEIR USE IN COMBINATION THERAPY TOGETHER WITH DIFFERENT ANTIBIOTICS | PNISR, MRPS18A, MRPS35 | MMP9 2547/4885MMP8 1432/4885MMP2 938/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.